183 related articles for article (PubMed ID: 21174093)
21. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Pflugfelder A; Eigentler TK; Keim U; Weide B; Leiter U; Ikenberg K; Berneburg M; Garbe C
PLoS One; 2011 Feb; 6(2):e16882. PubMed ID: 21359173
[TBL] [Abstract][Full Text] [Related]
22. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
26. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.
Enk AH; Nashan D; Rübben A; Knop J
Cancer; 2000 May; 88(9):2042-6. PubMed ID: 10813715
[TBL] [Abstract][Full Text] [Related]
27. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
[TBL] [Abstract][Full Text] [Related]
29. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Yoon C; Papadopoulos NE; Camacho LH; McIntyre S; Alvarado GC; Bedikian AY; Hwu P; Kim KB
Melanoma Res; 2010 Feb; 20(1):43-7. PubMed ID: 19952963
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
[TBL] [Abstract][Full Text] [Related]
31. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P
J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161
[TBL] [Abstract][Full Text] [Related]
32. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
33. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
34. Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
Mattila K; Raanta P; Lahtela V; Pyrhönen S; Koskivuo I; Vihinen P
Anticancer Res; 2018 Nov; 38(11):6393-6397. PubMed ID: 30396963
[TBL] [Abstract][Full Text] [Related]
35. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A; Puzanov I; Dummer R; Schadendorf D; Hamid O; Robert C; Hodi FS; Schachter J; Pavlick AC; Lewis KD; Cranmer LD; Blank CU; O'Day SJ; Ascierto PA; Salama AK; Margolin KA; Loquai C; Eigentler TK; Gangadhar TC; Carlino MS; Agarwala SS; Moschos SJ; Sosman JA; Goldinger SM; Shapira-Frommer R; Gonzalez R; Kirkwood JM; Wolchok JD; Eggermont A; Li XN; Zhou W; Zernhelt AM; Lis J; Ebbinghaus S; Kang SP; Daud A
Lancet Oncol; 2015 Aug; 16(8):908-18. PubMed ID: 26115796
[TBL] [Abstract][Full Text] [Related]
39. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
40. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
